Pasar al contenido principal

BLOQUEAR LA ENTRADA DE VIRUS CON ENVUELTA EN CELULAS INMUNES: NUEVOS ANTICUERPOS MONOCLONALES E INTERRUPCION DE LA CASCADA INTRACELULAR

PID2019-109870RB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2019
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario FUNDACION PRIVADA INSTITUT DE RECERCA SOBRE IMMUNOPATOLOGIES-CAIXA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Understanding the neurological implications of acute and long COVID using brain organoids

  • García-González, Laura
  • Martí-Sarrias, Andrea
  • Puertas, Maria C.
  • Bayón-Gil, Ángel
  • Resa-Infante, Patricia
  • Martinez-Picado, Javier
  • Navarro, Arcadi
  • Acosta, Sandra
  • Acosta, Sandra
© 2023. Published by The Company of Biologists Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution and reproduction in any medium provided that the original work is properly attributed., As early as in the acute phase of the coronavirus disease 2019 (COVID-19) pandemic, the research community voiced concerns about the long-term implications of infection. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), like many other viruses, can trigger chronic disorders that last months or even years. Long COVID, the chronic and persistent disorder lasting more than 12 weeks after the primary infection with SARS-CoV-2, involves a variable number of neurological manifestations, ranging from mild to severe and even fatal. In vitro and in vivo modeling suggest that SARS-CoV-2 infection drives changes within neurons, glia and the brain vasculature. In this Review, we summarize the current understanding of the neuropathology of acute and long COVID, with particular emphasis on the knowledge derived from brain organoid models. We highlight the advantages and main limitations of brain organoids, leveraging their human-derived origin, their similarity in cellular and tissue architecture to human tissues, and their potential to decipher the pathophysiology of long COVID., This work is funded by Fundació la Marató de TV3 (2021-30/31/32) to S.A., J.M.-P. and A.N., and project 3D4COVID by Merck Sharp and Dohme Investigator Studies Program (code MISP# IIS 60258) to J.M.-P. and S.A. J.M.-P. is supported by grant PID2019-109870RB-I00 from Ministerio de Ciencia e Innovación. L.G.-G. is supported by a Margarita Salas Fellowship (2021UPF-MS-28) from Ministerio de Ciencia e Innovación, funded by the European Union-NextGenerationEU, Ministry of Universities and Recovery, Transformation and Resilience Plan, through Universitat Pompeu Fabra., Peer reviewed
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

Opportunities for CAR-T Cell Immunotherapy in HIV Cure

  • Campos-Gonzalez, Gerard|||0000-0002-5442-4963
  • Martínez Picado, Francisco Javier|||0000-0002-4916-2129
  • Velasco-Hernández, Talia|||0000-0003-2183-7443
  • Salgado, Maria|||0000-0003-1551-7216
Chimeric antigen receptor (CAR) technology is having a huge impact in the blood malignancy field and is becoming a well-established therapy for many types of leukaemia. In recent decades, efforts have been made to demonstrate that CAR-T cells have potential as a therapy to achieve a sterilizing cure for human immunodeficiency virus (HIV) infection. However, translation of this technology to the HIV scenario has not been easy, as many challenges have appeared along the way that hinder the consolidation of CAR-T cells as a putative therapy. Here, we review the origin and development of CAR-T cells, describe the advantages of CAR-T cell therapy in comparison with other therapies, and describe the major obstacles currently faced regarding application of this technology in the HIV field, specifically, viral escape, CAR-T cell infectivity, and accessibility to hidden reservoirs. Nonetheless, promising results in successfully tackling some of these issues that have been obtained in clinical trials suggest a bright future for CAR-T cells as a consolidated therapy.